The effects of ω3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial
The effects of ω3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial
复制标题
DOI：
10.1097/hjh.0b013e32832e1bd9
复制
发表时间：
2009-09-01
影响因子：
4.9
通讯作者：
Watts, Gerald F.
中科院分区：
文献类型：
--
作者：
Mori, Trevor A.;Burke, Valerie;Watts, Gerald F.
背景与目的慢性肾脏病（CKD）与心血管疾病（CVD）风险增加相关。高血压是CKD进展的主要决定因素。Omega-3脂肪酸（Omega 3FA）通过改善血压、心率、血管反应性和血脂来预防CVD。辅酶Q（10）（CoQ）可以改善血压和血管功能。本研究确定了ω-3FA和辅酶Q在改善3- 4期非糖尿病CKD患者的心血管特征，特别是血压和心率方面是否具有独立或相加的作用。方法在双盲、安慰剂对照的干预中，患者被随机分配至ω-3FA（4 g）、辅酶Q（200 mg）、补充剂或对照（4 g），结果85例患者随机分组，年龄56.5 ± 1.4岁，BMI 27.3 ± 0.5 kg/m2，仰卧位血压125.0/72.3 mmHg，肾小球滤过率35.8 ± 1.2 ml/min/1.73 m2。74人完成了研究。ω-3FA，而不是辅酶Q，降低24小时动态心率（P
Background and objective Chronic kidney disease (CKD) associates with increased cardiovascular disease (CVD) risk. Hypertension is a major determinant of progression of CKD. Omega-3 fatty acids (omega 3FA) protect against CVD via improvements in blood pressure, heart rate, vascular reactivity and serum lipids. Coenzyme Q(10) (CoQ) may improve blood pressure and vascular function. This study determined whether omega 3FA and CoQ have independent or additive effects in improving the cardiovascular profile, particularly blood pressure and heart rate, in nondiabetic patients with CKD stages 3-4.Methods In a double-blind, placebo-controlled intervention, patients were randomized to either omega 3FA (4 g), CoQ (200 mg), both supplements or control (4 g), daily for 8 weeks.Results Eighty-five patients aged 56.5 +/- 1.4 years; BMI 27.3 +/- 0.5 kg/m(2); supine blood pressure 125.0/72.3 mmHg; and glomerular filtration rate 35.8 +/- 1.2 ml/min/1.73 m(2), were randomized. Seventy-four completed the study. omega 3FA, but not CoQ, reduced 24-h ambulatory heart rate (P